Pure Global AI
NCT06348173Completed

Response and Remission to Treatment With Anti-IL5/IL5R Antagonists

Response and Remission to Treatment With Anti-IL5/IL5R Antagonists in a Real-world Setting
Université de MontréalClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Asthma
Drug/Device/Intervention
Mepolizumab
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Université de Montréal
Location
Montréal, Canada
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2023
End date
Nov 30, 2023
Enrollment
109 participants
Primary outcome

Response to IL5/IL5R antagonists one year after cohort entry among subjects fulfilling and not fulfilling the original RCT inclusion criteria,Remission rate with IL5/IL5R antagonists one year after cohort entry in subjects fulfilling and not fulfilling the original RCT inclusion criteria

Summary

The aim of this retrospective observational study is to compare the response and remission
 rate after treatment with IL5/IL5-R antagonists in asthmatics who would and would have not
 met the inclusion criteria of the original randomized clinical trials.
 
 This study will be performed using the charts of the patients.

ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaPredominantly allergic asthma
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06348173
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06348173 through Pure Global AI's free database. This phase not specified trial is sponsored by Université de Montréal and is currently Completed. The study focuses on Asthma. Target enrollment is 109 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.